Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
FDA approves blinatumomab for consolidation in Ph-negative B-cell precursor ALLNov 6Regulatory decisionAmgenblinatumomab
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
MD Anderson's phase 2 trial of subcutaneous blinatumomab in MRD-positive B-ALL listed as suspendedOct 8Trial updateAmgenblinatumomab
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOSAug 4Quarterly updateAMG-513Amgen